CLINICAL TRIAL

Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2025-05-28
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

University Hospital Basel Switzerland

Watch author

Derived topics and classifications

psilocybin psilocin Depression Anxiety Addiction Receptor Pharmacology Consciousness Personality Change Spirituality Healthy Volunteers Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding StudyClinicalTrials.gov · 2023-03-20 Serotonergic Psychoactive Compounds as a Treatment for Addiction, Anxiety, and Depression: Their Efficacy and LegalityFurman University Scholar Exchange (Furman University) · 2019-01-01 An Overview on the Taxonomy, Phylogenetics and Ecology of the Psychedelic Genera Psilocybe, Panaeolus, Pluteus and GymnopilusFrontiers in Forests and Global Change · 2022-05-23 Double-blind Placebo-controlled Naturalistic Study of Microdosing With Psilocybin: Effects on Brain Activity, Behavior, Cognition, Creativity, and Mental HealthClinicalTrials.gov · 2021-12-16